China-based biopharmaceutical company Impact Therapeutics has reportedly secured RMB 250 million (USD 34.5 million) in a Series D++ financing round, co-led by a globally renowned industry investment institution and a prominent insurance fund. The funds raised will be directed towards the commercialization of its core product, senaparib, a PARP1 inhibitor, as well as the global clinical development of other compounds and the research and development of multiple early-stage programs.
Senaparib: A Promising PARP1 Inhibitor
Senaparib, developed in-house by Impact Therapeutics, is a PARP1 inhibitor that has garnered orphan drug designation (ODD) in the US for its potential in treating small-cell lung cancer in combination with temozolomide. This designation in August 2022 highlights the drug’s potential to address unmet medical needs. Early clinical trials have demonstrated senaparib’s promising anti-tumor effects, with significant efficacy observed in ovarian cancer, meeting the primary endpoint in the pivotal Phase III FLAMES study.
Regulatory Progress and Global Development
A New Drug Application (NDA) for senaparib was accepted for review in China late last year, marking a significant step towards its potential market approval. The proceeds from the Series D++ financing round will support the global clinical development of senaparib and other compounds in Impact Therapeutics’ pipeline, bolstering the company’s research and development efforts in bringing innovative treatments to patients worldwide.-Fineline Info & Tech
Leave a Reply